Form 4: BioXcel Director Converts RSUs to Common Stock

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock on August 31, 2025.

Summary

• David J. Mack, a Director of BioXcel Therapeutics, Inc. (BTAI), converted 1,693 Restricted Stock Units (RSUs) into common stock.
• The transaction occurred on August 31, 2025, as part of a routine vesting schedule.
• Following this conversion, Mack directly owns 16,930 shares of BioXcel Therapeutics common stock.
• He also directly holds 3,387 Restricted Stock Units.
• The RSUs involved were part of a grant of 20,317 units on November 21, 2024, which vest in twelve equal monthly installments beginning November 30, 2024, contingent on his continued service as a Director.

Sentiment

Score: 7

Explanation: The filing reports a routine conversion of Restricted Stock Units into common stock by a director, which is a standard compensation event and indicates continued alignment of interests.

Positives

• Director David J. Mack increased his direct ownership of BioXcel Therapeutics common stock by 1,693 shares through the conversion of Restricted Stock Units, aligning his interests with shareholders.
• The vesting and conversion of RSUs indicate the director's continued service to the company.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is a common occurrence across all industries for publicly traded companies. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns management interests with shareholder value.

Next Steps

• Remaining Restricted Stock Units will continue to vest in equal monthly installments, subject to the director's continued service.

Key Dates

Recommendation

The Form 4 filing details a routine conversion of Restricted Stock Units into common stock by a director. This type of transaction is a standard part of executive compensation and does not provide new fundamental information to warrant a change in investment recommendation. It primarily reflects the vesting schedule of previously granted equity awards.

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, David J. Mack, Restricted Stock Units, RSU conversion, Director, Common Stock